Nanobiotix (NASDAQ:NBTX) Stock Price Up 1.1% - Should You Buy?

Nanobiotix S.A. (NASDAQ:NBTX - Get Free Report)'s stock price traded up 1.1% during trading on Tuesday . The stock traded as high as $4.17 and last traded at $4.15. 1,204 shares were traded during trading, a decline of 92% from the average session volume of 15,564 shares. The stock had previously closed at $4.10.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Guggenheim cut their price target on shares of Nanobiotix from $12.00 to $8.00 and set a "buy" rating on the stock in a report on Friday, April 4th. UBS Group raised shares of Nanobiotix to a "hold" rating in a research note on Monday, February 17th.

Nanobiotix Stock Up 2.6%

The company's 50 day moving average is $3.57 and its 200 day moving average is $3.44.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC purchased a new position in Nanobiotix in the 4th quarter worth about $29,000. Millennium Management LLC bought a new position in Nanobiotix during the 4th quarter worth about $39,000. Jane Street Group LLC bought a new position in Nanobiotix during the 4th quarter worth about $73,000. Finally, OLD Mission Capital LLC bought a new position in Nanobiotix during the 4th quarter worth about $139,000. Hedge funds and other institutional investors own 38.81% of the company's stock.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.